XM does not provide services to residents of the United States of America.

Health insurer Centene eases investor fears with better-than-expected profit



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 4-Health insurer Centene eases investor fears with better-than-expected profit</title></head><body>

Company maintains annual profit forecast despite higher medical costs

Analysts surprised by better-than-expected quarter amid Medicaid pressure

Centene shares jump nearly 12% after earnings beat

Adds details from company's conference call in paragraphs 5 and 6, updates shares in paragraph 2

By Sriparna Roy and Unnamalai L

Oct 25 (Reuters) -Centene CNC.N beat Wall Street estimates for third-quarter earnings on strength in its commercial health insurance plans and maintained its annual profit forecast, easing investor fears after dour targets from rivals last week.

Shares of the health insurer jumped nearly 12% to $68.92 in early trading on Friday. They fell 16% in the last week after rivals Elevance ELV.N and UnitedHealth UNH.N warned of high costs in government-backed insurance plans.

Costs for insurers providing Medicaid plans have been elevated after a federal policy that required insurers to keep low-income Americans enrolled in health plans during the COVID-19 pandemic ended last year, and left the insurers with more sick patients.

The quarter was "much better than expected", said Baird analyst Michael Ha, adding that it was a "surprise" after peers reported "unprecedented levels" of Medicaid pressure last week.

Centene said it expects costs to ease next year as the 'mismatch' between what states pay insurers to cover Medicaid members and the amount the insurers spend on care for the members minimizes.

It is "not a matter of if, but when, we get back to equilibrium", CFO Drew Asher said in a call with analysts.

For the full year, Centene expects a medical loss ratio — the percentage of premiums spent on medical care — of 88.3% to 88.5%, compared with analysts' average estimate of 87.93%, according to data compiled by LSEG.

It reported a ratio of 89.2% for the quarter ended Sept. 30. Analysts had expected 88.03%.

Despite higher costs, the company maintained its annual profit forecast of greater than $6.80 per share, compared with analysts' expectation of $6.73.

Investors had been preparing for a potential cut to Centene forecast, said Stephens analyst Scott Fidel.

Centene reported quarterly profit of $1.62 per share, above analysts' average estimate of $1.33.



Persistant high costs have weighed on health insurer stocks https://tmsnrt.rs/3YCKpLu


Reporting by Amina Niasse in New York City, Sriparna Roy and Unnamalai L in Bengaluru; Editing by Shilpi Majumdar and Shinjini Ganguli

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.